<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147548</url>
  </required_header>
  <id_info>
    <org_study_id>ETILANCE - ETI 175</org_study_id>
    <nct_id>NCT02147548</nct_id>
    <nct_alias>NCT02143895</nct_alias>
  </id_info>
  <brief_title>Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly</brief_title>
  <official_title>Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly. A Monocentric, Randomized, Cross-over, Double-blind Clinical Study Versus Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocodex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocodex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of etifoxine (an anxiolytic) compared to&#xD;
      lorazepam (a benzodiazepine anxiolytic) on vigilance and cognitive functions in the elderly.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reaction time (RTI) of Cambridge Neuropsychological Test Automated Batteries (CANTAB)</measure>
    <time_frame>2 hours after the study treatment intake</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>etifoxine (Anxiolytic)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>etifoxine, 100 mg, a single oral intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lorazepam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>lorazepam, 2 mg, a single oral intake</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules of Placebo, a single oral intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etifoxine</intervention_name>
    <arm_group_label>etifoxine (Anxiolytic)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lorazepam</intervention_name>
    <arm_group_label>lorazepam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman aged from 65 to 75 years&#xD;
&#xD;
          -  Right-handed subject (Edinburgh Handedness inventory)&#xD;
&#xD;
          -  Subject having signed the consent form&#xD;
&#xD;
          -  Subject having agreed to be listed on the French National Healthy Volunteers database&#xD;
&#xD;
          -  Subject affiliated or beneficiary to French social insurance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject presenting a neurological or psychiatric disease notably cognitive,&#xD;
             progressing&#xD;
&#xD;
          -  Anxious subject (Hamilton score &gt; 7 and/or Spielberger score &gt; 51 for a man or &gt; 61&#xD;
             for a woman)&#xD;
&#xD;
          -  Left-handed subject (Edinburgh Handedness inventory)&#xD;
&#xD;
          -  Subject presenting a not corrected visual disease or a motor function disease that&#xD;
             could interfere with tests realization&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Subject taking one or more psychotropics or apparent products&#xD;
&#xD;
          -  Subject having taken, during the previous month, one or more drugs that could&#xD;
             interfere with study drugs metabolism&#xD;
&#xD;
          -  Subject drinking too much coffee or tea (&gt; 4 cups per day) or alcohol (&gt;Â½ liter of&#xD;
             wine or equivalent per day)&#xD;
&#xD;
          -  Subject presenting contra-indication to one of the drugs used in the study&#xD;
&#xD;
          -  Subject with past history of intolerance to drugs used in the study&#xD;
&#xD;
          -  Subject not capable to use the CANTAB cognitive evaluation system&#xD;
&#xD;
          -  Subject which may not be able to participate to the whole study&#xD;
&#xD;
          -  Subject under tutelage or guardianship&#xD;
&#xD;
          -  Subject not able to well-understand French and so to understand cognitive tests&#xD;
&#xD;
          -  Subject not capable to swallow capsules&#xD;
&#xD;
          -  Subject participating to another study or in exclusion period (3 months after a&#xD;
             previous trial).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre d'Investigation Clinique, CIC 1403 INSERM/CHRU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>May 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <last_update_submitted>July 26, 2016</last_update_submitted>
  <last_update_submitted_qc>July 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorazepam</mesh_term>
    <mesh_term>Etifoxine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

